Stocklytics Platform
Asset logo for symbol MRSN
Mersana Therapeutics
MRSN65
$0.75arrow_drop_up10.73%$0.07
Penny Stock
Asset logo for symbol MRSN
MRSN65

$0.75

arrow_drop_up10.73%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Mersana Therapeutics (MRSN) Stocklytics Forecast

Mersana Therapeutics Inc (MRSN) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) for the treatment of cancer. With its innovative platform and strong pipeline, Mersana Therapeutics has gained the attention of investors and analysts in the biotech industry. The company's stock price has been volatile in recent years, reflecting the uncertainty and risks associated with early-stage biotech companies.
Looking ahead, some analysts have provided price forecasts for Mersana Therapeutics Inc (MRSN) stock. According to these forecasts, MRSN stock is expected to experience significant growth in the coming years. The average price target for MRSN stock is $27.50, indicating a potential upside of over 100% from the current price. This indicates that many analysts view Mersana Therapeutics as undervalued and believe that the company's pipeline of ADC candidates has strong potential for success.
add Mersana Therapeutics  to watchlist

Keep an eye on Mersana Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Mersana Therapeutics (MRSN) stock?

Analysts have set a target price of $9.83 for Mersana Therapeutics (MRSN), based on forecasts from 6 analysts. The predicted price range extends from a high of $15 to a low of $5. This represents a potential increase of up to 1.88K% and a decrease of 559.63% from the current price of $0.76. These forecasts are as of 2022 Dec 05.
help

What are the analyst ratings for Mersana Therapeutics (MRSN) stock?

The analyst ratings for Mersana Therapeutics (MRSN) are distributed as follows: 8 analysts recommend buying, 2 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 10 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Mersana Therapeutics .
help

What is the AI price prediction for Mersana Therapeutics (MRSN) stock?

At present, there is no AI or machine-learning-based price prediction available for Mersana Therapeutics (MRSN) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level